← All trials
NCT02104830
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2013
- Primary completion
- Jun 1, 2014
- Completion date
- Oct 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 135
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- BiocadLead sponsor
- Bangalore Institute of OncologyOverall official - principal investigator
- Donetsk City Municipal Oncology DispensaryOverall official - principal investigator
- Donetsk Regional oncology centersOverall official - principal investigator
- Zakarpatskii Regional Clinical Oncology DispensaryOverall official - principal investigator
- Kharkiv Regional Clinical Oncology CenterOverall official - principal investigator
- Vinnitskii Regional Oncology DispensaryOverall official - principal investigator
- Non-State Healtcare Institution Road Clinical Hospital of Open Joint Stock Company Russian RailwaysOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Russian Academy of Medical SciencesOverall official - principal investigator
- BiocadStudy director
- Mordovia State UniversityOverall official - principal investigator
- Russian MilitaryOverall official - principal investigator
- Government of TatarstanOverall official - principal investigator
- M.S. Ramaiah Medical College, Bangalore, IndiaOverall official - principal investigator
- Narayana Hrudayalaya LimitedOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.